According to a new report, published by KBV research, The Global Skin Cancer Diagnostics Market size is expected to reach $12.8 billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.
The Melanoma market is expected to witness a CAGR of 6.2% during (2024 - 2031). The melanoma segment is driven by the critical need for early detection and accurate diagnosis due to the aggressive nature of melanoma. Although melanoma is less common than non-melanoma skin cancers, it poses a significant risk due to its potential to metastasize rapidly. Furthermore, ongoing research and development have led to innovative diagnostic tests, including genomic and proteomic profiling, enhancing diagnostic accuracy and opening new revenue streams.
The skin biopsy segment dominated the 2020 in 2023; thereby, achieving a market value of $3.5 billion by 2031. A skin biopsy involves the removal of a sample of skin tissue, which is then inspected under a microscope by a pathologist to determine whether cancer cells are present in the sample. For the diagnosis of melanoma or skin cancer, this process is the gold standard because it offers a diagnosis that is both conclusive and extremely accurate.
The Laboratories market is expected to witness a CAGR of 5.6% during (2024 - 2031). Laboratories are equipped with advanced diagnostic technologies and staffed by skilled pathologists and technicians who perform detailed skin biopsies and other sample analyses. The precision and reliability of laboratory-based diagnostics make them essential for confirming skin cancer diagnoses and determining the exact type and stage of cancer.
Full Report: https://www.kbvresearch.com/skin-cancer-diagnostics-market/
The North America region dominated the Global Skin Cancer Diagnostics Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $4.6 billion by 2031. The Europe region is exhibiting a CAGR of 5% during (2024 - 2031). Additionally, The Asia Pacific region would exhibit a CAGR of 5.9% during (2024 - 2031).
By Type
By Test Type
By End-use
By Geography
Unique Offerings 
